107results about How to "Binding block" patented technology

Belonging to the field of tumor treatment and molecular immunology, the invention relates to an anti-CTLA4-anti-PD-1 bifunctional antibody, a pharmaceutical composition and use thereof. Specifically, the anti-CTLA4-anti-PD-1 bifunctional antibody comprises: a PD-1 (programmed death-1) targeted first protein functional region, and a CTLA4 (cytotoxic T lymphocyte sociated antigen 4) targeted second protein functional region. The bifunctional antibody provided by the invention can well bind to CTLA4 and PD-1 specifically, specifically remove the immunosuppression of CTLA4 and PD-1 on the body, and activate T lymphocytes, thus having good application prospect.

The present invention belongs to the field of tumor treatment and molecular immunology, and relates to an anti-PD1 monoclonal antibody, a pharmaceutical composition and uses thereof. In particularly, the present invention relates to a monoclonal antibody or an antigen-binding fragment thereof, wherein the heavy chain variable region of the monoclonal antibody comprises CDR having an amino acid sequence represented by SEQ ID NO:9-11, and / or the light chain variable region of the monoclonal antibody comprises CDR having an amino acid sequence represented by SEQ ID NO:12-14. According to the present invention, the monoclonal antibody can well and specifically bind to PD1, can specifically release the immunosuppression of PD1 on body, and can activate T lymphocytes.

The invention belongs to the fields of oncotherapy and molecular immunology, and relates to an anti-PD-1 (programmed cell death 1) monoclonal antibody as well as pharmaceutical composition and an application thereof, in particular to a monoclonal antibody or an antigen binding fragment thereof. The heavy chain variable region of the monoclonal antibody contains CDR with amino acid sequences represented as SEQ ID NO: 13-15; and / or the light chain variable region of the monoclonal antibody contains CDR with amino acid sequences represented as SEQ ID NO: 16-18. The monoclonal antibody can be specifically bound with PD-1 very well, specifically remove immunosuppression of PD-1 on an organism and activate T lymphocytes.

A monoclonal antibody for PDL-1 (programmed cell death-ligand 1) or its antigen binding fragment is provided. The monoclonal antibody can specifically bind with PDL-1, inhibition of PDL-1 upon body immunity is resolved, and T-lymphocytes are activated. A pharmaceutical composition containing the monoclonal antibody and application of the monoclonal antibody are also provided.

The invention relates to the technical field of antibody engineering and specifically discloses an anti-PCSK9 monoclonal antibody. The invention comprises an amino acid sequence coding an antibody variable region and a CDR region as well as an acquisition method and an application of the monoclonal antibody. The monoclonal antibody disclosed by the invention is prepared by the following steps: screening out anti-PCSK9 monoclonal antibodies from a phage library; performing affinity maturation by a method of establishing phage library through strand displacement; screening the mutant libraries of light-chain CDR1, 2, and 3 regions of the monoclonal antibody obtained by primary screening, and selecting the monoclonal antibodies with relatively high affinity; and screening the mutant libraries of heavy-chain CDR1, 2, and 3 to finally obtain the anti-PCSK9 monoclonal antibody with high affinity. In the invention, the obtained PCSK9 antibody has good affinity on PCSK9 and can inhibit combination of the PCSK9 with ligand thereof and can be used for treating dyslipidemia, cardiovascular and cerebrovascular diseases and thrombosis-obstructive diseases.

The invention discloses a preparation method of an exosome for expressing ACE2 protein. The preparation method comprises the following steps: constructing an hMSC human mesenchymal stem cell line forstably expressing human ACE2 protein; and extracting exosome rich in ACE2 protein from a culture supernatant of an hMSC human bone marrow mesenchymal stem cell line through an ultracentrifugation method. The exosome can neutralize new coronavirus, and has treatment and prevention potential on the novel coronavirus. Therefore, the exosome for expressing the ACE2 protein, which is prepared by the method, can be applied to the preparation of anti-novel coronavirus SARS-CoV2 medicines.

The invention relates to the technical field of antibody engineering and in particular discloses a PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) resistant monoclonal antibody. The monoclonal antibody disclosed by the invention comprises an amino acid sequence coding an antibody variable region and a CDR region. The invention further discloses an acquiring method and application of the monoclonal antibody. The method comprises the following steps: screening a PCSK9 resistant monoclonal antibody from a phage antibody library, performing affinity maturation through a method for constructing the phage antibody library by virtue of strand displacement, performing mutant library-construction screening on light-chain CDR1, 2 and 3 regions of the monoclonal antibody obtained by preliminaryscreening, selecting a monoclonal antibody with high affinity, performing mutant library-construction screening on heavy-chain CDR1, 2 and 3 regions of the monoclonal antibody, and finally screeningthe PCSK9 resistant monoclonal antibody with high affinity. The PCSK9 resistant monoclonal antibody obtained in the invention has excellent affinity to PCSK9, is capable of inhibiting binding betweenthe PCSK9 and ligands thereof, and can be used for treating dyslipidemia, cardiovascular and cerebrovascular diseases and thrombosis-obstructive diseases.

The invention relates to a novel human monoclonal antibody of coronavirus and application of the novel human monoclonal antibody. The antibody can be specifically combined with the 2019-nCoV RBD, the combination of the 2019-nCoV RBD and ACE2 is blocked, and the infection of the 2019-nCoV is inhibited.

The invention belongs to the field of immunology and relates to an anti-IL-1beta (anti-interleukin-1beta) antibody as well as a medicine composition and application thereof. Specially, the invention relates to the anti-IL-1beta antibody or an antigen binding fragment thereof. The heavy chain variable region of the antibody comprises HCDR1-3 (heavy chain complementary determining region 1-3) of which amino acid sequences are shown in SEQ ID NO:17-19 in the description respectively; and the light chain variable region of the antibody comprises LCDR1-3 (light chain complementary determining region 1-3) of which amino acid sequences are shown in SEQ ID NO:20-22 in the description respectively. The antibody provided by the invention is capable of effectively binding human IL-1beta, blocking binding of IL-1beta with a receptor IL-1R1 and inhibiting activation of a downstream signal channel of IL-1beta, and has the potential of preparing medicines for preventing and treating autoimmune diseases, cryopyrin-associated periodic syndromes of children and adults, systemic juvenile idiopathic arthritis, gouty arthritis, cardiovascular diseases or tumors.

The invention discloses a higher-functionality antihuman CTLA4 antibody with high affinity and high specificity as well as multi-antigen recognition epitopes. The CTLA4 monoclonal antibody disclosed by the invention can be specifically combined with CTLA4 and has the advantages that the binding of the CTLA4 with B7 protein can be effectively blocked, down regulation of the CTLA4 can be specifically relieved and T cells are activated to secrete cytokines. All functions reach or exceed the level of a unique CTLA4 target drug Yervoy in the current market, and partial antibodies are different fromantigen epitopes of the Yervoy, so that greater diversity is achieved.

The invention relates to a hybridoma cell strain SZ-125(3D2) with the prevention number of CGMCC NO.2501 and a bi-functional monoclonal antibody capable of anti-human von willbrand factor-A3 secreted by the hybridoma cell strain. The monoclonal antibody is combined with the VWF A3 to block the combination of the VWF A3 and collagen and simultaneously influences the configuration of domain A1, thereby destroying the original domain A1 configuration capable of combining platelet GPIb alpha and achieving the aim of blocking the interaction of the VWF A1 and the GPIb alpha, so that not only combination of the VWF A3 and the collagen is blocked but also the combination of the VWF A1 and the platelet GPIb alpha is blocked. Thus, the monoclonal antibody can be used for preparing anti-artery thrombosis medicine with anti-platelet adhesion activity.